We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Central serous chorioretinopathy is a retinal disorder that has been linked to the systemic use of corticosteroids. Recently, it has also been reported after local administration of corticosteroids via inhaled and intranasal, epidural, intra-articular, topical dermal, and periocular routes.
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
Product Safety Report for Esapharma Movate Steroid Cream presenting a serious chemical risk.
Neonatal meningitis is a common cause of death and long-term disability among children, particularly in developing countries
Product Safety Report for Vixa Skineal Steroid Cream presenting a serious chemical risk.
Product Safety Report for Front Pharmaceutical Tydineal Steroid Cream presenting a serious chemical risk.
Public Assessment Report (PAR) reviewing available safety data for topical steroid withdrawal reactions, which have been associated with topical corticosteroids.
Dengue is a disease caused by a virus transmitted by mosquitoes, occurring in many resource-limited countries
Product Safety Report for Bliss GVS Pharma Funbact-A Steroid Cream presenting a serious chemical risk.
Paper prepared by the COVID-19 Clinical Information Network (CO-CIN).
Rarely, severe adverse effects can occur on stopping treatment with topical corticosteroids, often after long-term continuous or inappropriate use of moderate to high potency products. To reduce the risks of these events, prescribe the topical corticosteroid of lowest potency needed...
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.